Symposia


WIN 2018 Symposium
June 25 - 26, 2018

We are excited to celebrate our 10th year Anniversary edition of the WIN Symposia at the WIN Symposium 2018 in Paris, France on 25-26 June 2018.

The WIN Symposium Organizing Committee has chosen “Global Implementation of Precision Oncology: WINning the War against Cancer” as the theme for this celebratory event.

Prominent and distinguished speakers at this special event include:
- Elizabeth Blackburn, Nobel Prize in Physiology or Medicine, President Salk Institute, USA
- Carl H. June, inventor of CAR T-cell therapies, 2017 David A. Karnofsky Memorial Award ASCO, Perelman School of Medicine, USA
- James H. Doroshow, Deputy Director for Clinical and Translational Research, NCI, USA
- Josep Tabernero, ESMO President Elect, Director Vall d’Hebron Institute of Oncology (VHIO), Spain
- Richard L. Schilsky, Senior Vice President and Chief Medical Officer ASCO, USA
- Ellen V. Sigal, Founder and Chairperson Friends of Cancer Research, USA

For more details, please visit our dedicated symposium website: https://www.winsymposium.org


Past events


WIN 2017 Symposium

WIN 2017 Symposium
June 26 - 27, 2017

The WIN 2017 Symposium with the theme ‘Expediting Global Innovation in Precision Cancer Medicine’ was held in Paris, France, June 26-27, 2017. The overarching goal of our symposium was to share information to promote and accelerate cutting edge investigations and use of personalized, targeted cancer therapy.



Highlights from the WIN 2017 Symposium, 26–27 June 2017, Paris, France: ‘Expediting Global Innovation in Precision Cancer Medicine’

Speakers

ecancer Medical Science Conference Report


WIN 2016 Symposium

WIN 2016 Symposium
June 27 - 28, 2016

The WIN 2016 Symposium “Innovative Approaches to Improve Cancer Patient Outcomes”, June 27-28th was the eighth in a series of symposia dedicated to advancing personalized cancer medicine. It was a successful unique forum that brought leaders representing all stakeholders - academia, pharma, biotech / life sciences, regulatory, and health payer - together from around the globe.


Plenary Session 1: Welcome and Opening remarks:
Monday, June 27, 2016

Welcome

Speakers

John Mendelsohn WIN Chairman


Patients' and Advocacy Groups Perspectives:

No innovation about us without us

Speakers

Francesco de Lorenzo



Patient perspectives

Speakers

Matt Ellefson


Plenary Session 2: New tools for early diagnosis, selecting therapies and monitoring:


Speakers

Chairmen: Alex Drilon, Don Gibbons


Part 1: New Strategies to Improve Outcomes:

Keynote Lecture: A systems biology approach to elucidating and targeting functional tumor dependencies from patient-derived RNASeq profiles

Speakers

Andrea Califano



Affordable next-generation sequencing to support therapeutic decision-making

Speakers

Elaine Mardis


Part 2: Enabling Technologies: Opportunities for Liquid Biopsies:

Monitoring the cancer genome in plasma using circulating tumor DNA

Speakers

Nitzan Rosenfeld



Serum miRNAs as diagnostic and prognostic tools in GI malignancies

Speakers

Ajay Goel



Harnessing the biology of exosomes for diagnosis and treatment of cancer

Speakers

Raghu Kalluri


Part 3: A Scientist's View of Tumor Changes under Therapeutic Pressure:

Liquid biopsies to track clonal evolution and resistance to EGFR inhibition in mCRC

Speakers

Alberto Bardelli


Plenary Session 3: Innovative clinical trials to substantially improve outcome:


Speakers

Chairpersons: Razelle Kurzrock, Christophe Le Tourneau


Part 1: Immune Approaches and Combinations of Targeted Therapies:

Keynote Lecture: Paths to the Curative Treatment of Cancer, ABL001: A Future Case Study?

Speakers

William Sellers



Combination trial designs: How do we get efficiently to the most effective and tolerable combination regimen?

Speakers

Susan Galbraith


Part 2: Right Treatment Sequencing:

Towards Using Epigenetic Therapy to Improve Cancer Immunotherapy

Speakers

Daniel De Carvalho


Part 3: Forum: Is the Current Design of Precision Medicine Studies the Right One? Lessons from the Shiva Trial:

Pro Presentation

Speakers

Christophe Le Tourneau



Con Presentation

Speakers

Razelle Kurzrock


Plenary Session 4: Relevant models and critical preclinical data before moving to the clinic:
Tuesday, June 28, 2016


Speakers

Chairmen: Alan Spatz, Brian Leyland-Jones



Keynote Lecture: Scientific wellness and cancer

Speakers

Leroy Hood



Preclinical strategies for precision medicine in colorectal cancer: Challenges and opportunities

Speakers

Livio Trusolino



Cancer organoids: Limiting the need for animal models?

Speakers

Robert G.J Vries



New challenges in drug development


Special Plenary Session:

Results of MINDACT clinical trial

Speakers

Chairpersons: Martine Piccart, Thomas Tursz Suzette Delaloge


Plenary Session 5:

Expediting precision cancer medicine

Speakers

Forum chaired by John Mendelsohn, Participants: Martine Piccart, Bruce E. Johnson, Amir Onn, Richard L. Schilsky, William Sellers, Josep Tabernero, Thomas Tursz, Chang Sik Yu


Plenary Session 6: Translation of big data into clinical opportunities:


Speakers

Chairmen: Eitan Rubin, Yves Lussier


Part 1: Lung cancer:

Keynote Lecture: The impact of next generation sequencing on the outcomes of patients with lung cancer

Speakers

Bruce E. Johnson


Part 2: Colorectal cancer:

CRC subtypes: from molecular signatures to therapeutic opportunities

Speakers

Rodrigo Dienstmann


Part 3: Breast cancer:

Personalizing breast cancer therapy

Speakers

Funda Meric-Bernstam


Part 4: Debate: Is big data ready to improve patient outcomes or is it a new generation of garbage in/ garbage out?:

Pro presentation/Con presentation

Speakers

Yves Lussier Gordon B. Mills






WIN 2015 Symposium

WIN 2015 Symposium
June 29 - 30, 2015

The WIN 2015 Symposium, on the theme of “Novel Targets, Innovative Agents, Advanced Technologies: A WINNing Strategy?” featured a global array of many of the world’s leading experts in personalized cancer medicine - from academia, pharma, biotech, and governmental organizations.


Plenary Session 1: Opening:
Monday, June 29, 2015

Opening Addresses

Speakers

John Mendelsohn


WIN 2015 Keynote Opening Lecture:

The Era of Precision Cancer Medicine: A worldwide effort and challenge - Introduction to WIN Consortium

Speakers

John Mendelsohn


Plenary Session 2: Targeting immune mechanisms:
Monday, June 29, 2015


Speakers

Chairmen: Alexander Eggermont, Robert Iannone


Keynote Lecture:

Targeting immune mechanisms

Speakers

James Allison



Natural killer immunity and cancer immunome

Speakers

Angel Porgador



What T-cells see on human cancer

Speakers

Ton Schumacher


Plenary Session 3: Systems biology and new approaches to support personalized cancer care:
Monday, June 29, 2015


Speakers

Chairmen: Thomas Tursz, Chang Sik Yu


Keynote Lecture:

A systems biology approach to precision cancer medicine

Speakers

Andrea Califano



Personalized combinatorial approaches to closing down all the key oncogenic drivers

Speakers

Brian Leyland-Jones



Battle-2 Trial: Mutational landscape and clinical outcome

Speakers

Waun Ki Hong



Drug target activation mapping through a proteomic CLIA assay: A companion diagnostic engine for personalized medicine trials

Speakers

Emanuel F. Petricoin


Plenary Session 4: Next generation of trials with targeted therapies:
Monday, June 29, 2015


Speakers

Chairman: Richard L. Schilsky



Round table of pharma and academic experts

Speakers



WINTHER trial: Interim results and lessons learnt



WINTHER trial: An SME driven EUFP7 program to create an industry standard tool to optimize therapeutic decision making

Speakers

Mohammad Afshar


Plenary Session 5: WIN Consortium - next generation of trials with targeted therapies:
Monday, June 29, 2015


Speakers

Chairmen: John Mendelsohn, Waun Ki Hong



SIMS - Simplified INterventional Mapping System for the identification of druggable activated pathways

Speakers

Vladimir Lazar



SPRING - Rolling tri-therapy combinations of targeted drugs in second line of metastatic NSCLC

Speakers

Razelle Kurzrock



SUMMER - Elimination of relapse through innovative adjuvant targeted therapeutics in stage II and III NSCLC

Speakers

Don Gibbons



BOOSTER - An integrative program for the discovery & validation of new blood biomarkers for NSCLC for use in early diagnosis (stage I)

Speakers

Harvey Pass



Oral presentation of awarded posters

Speakers

Chairmen: Catherine Bresson, Marinus Lobbezoo


Plenary Session 6: New avenues: Big trials and big data:
Tuesday, June 30, 2015


Speakers

Chairmen: Katherine Galvin, Benjamin Neel


Keynote Lecture:

A perspective on NCI strategy and trials

Speakers

James Doroshow



ASCO's initiatives in personalized medicine



Meta analyses of 50,000 patients in personalized cancer trials

Speakers

Razelle Kurzrock



New avenues for the development and evaluation of therapy

Speakers


Plenary Session 7: Multi-modality and multi-drug cancer therapy:
Tuesday, June 30, 2015


Speakers

Chairmen: C.S. Pramesh, Scott M. Lippman



Bottleneck problems in mutation-driven drug development and immunotherapy

Speakers



Combinating radiation and immunotherapy

Speakers

Ralph Weichselbaum


Plenary Session 8: Recent progress in specific tumor types:
Tuesday, June 30, 2015


Speakers

Chairmen: Jean-Francois Martini, Filippo de Braud



Intrinsic subtypes of colon cancer and their response to systemic therapy

Speakers



What is new in melanoma?

Speakers

Iman Osman



Cancer genomics of urothelial cancer and fibroepithelial tumors of the breast

Speakers

Bin Tean Teh


Plenary Session 9: Regulatory and funcing challenges in the era of personalized cancer medicine:
Tuesday, June 30, 2015


Speakers

Chairmen: Richard L. Schilsky, Kenneth Seamon


Keynote Lecture:

The EMA adaptive pathways approach to improve timely access for patients to new medicines

Speakers

Francesco Pignatti



End points and assessment of therapeutic efficacy in personalized cancer care

Speakers

Tatiana Powell



Importance of methodology certification and accreditations to perform assays



Use of targeted therapies and challenges for health payers

Speakers

Carole Redding Flamm



Challenges for foundations and cancer research organizations

Speakers

Jacques Raynaud



WIN2015 - Open Forum & Closing Remarks


WIN 2014 Symposium

WIN 2014 Symposium
June 23 - 24, 2014

The WIN 2014 Symposium which was held in Paris, June 23 and 24, 2014, was an exceptional global event entirely dedicated to breakthrough biomarker investigations and combination therapies for cancer. Over 400 delegates from more than 35 countries worldwide attended the Symposium.


Opening and Welcome Addresses:
Monday, June 23, 2014

Welcome Address

Speakers



WIN Consortium: Goals and strategy

Speakers

John Mendelsohn


Opening Address:

Another great journey: WIN in 21st century

Speakers

Trent Haywood


Plenary Session 1:
Monday, June 23, 2014

Molecular analysis of immune cells and immunotherapy

Speakers


Keynote Lecture:

Reinstating immunosurveillance: A prime goal of anticancer therapies and a strategic element for combination treatments

Speakers

Guido Kroemer



Molecular investigations of immune cells and tumor environment: The Ovarian Cancer Model

Speakers

George Coukos



Combining immunological and targeted agents: The way forward

Speakers

Axel Hoos



Tumor-infiltrating immune cells as classifiers and predictors of outcome

Speakers

Jerome Galon




Plenary Session 2:
Monday, June 23, 2014

What can we learn from hemato-oncology?

Speakers


Keynote Lecture:

Molecular pathways in the treatment of leukemia

Speakers

Bob Lowenberg



Role of mutations in epigenetic regulators in pathogenesis of myeloid malignancies

Speakers

Ross Levine



Combining interferon with targeted therapeutics to eliminate leukemia propagating cells in myeloproliferative neoplasms

Speakers

Eric Solary



Combination therapies in hematologic diseases

Speakers

Jesus Gomez Navarro



Systems medicine approach to optimize drugs and drug combinations for individual AML patients

Speakers

Olli Kallioniemi



General Discussion, Session 2

Speakers


Plenary Session 3:
Monday, June 23, 2014

Innovative therapeutic initiatives and models of cooperation

Speakers



Perspectives for effective cancer drug development: The EORTC SPECTA initiative

Speakers

Denis Lacombe



Clinical trial designs for incorporating multiple biomarkers in combination studies with targeted agents

Speakers

J. Jack Lee



General Discussion, Session 3

Speakers



Monday, June 23, 2014

POSTER AWARDING CEREMONY AND PRESENTATION OF AWARDED POSTERS

Speakers



Introduction Poster Award

Speakers



Oral presentation Summary Poster P4.01: Somatic mutation analysis in clinical tumour samples to select patients for experimental therapies

Speakers

Maider Ibarrola-Villava, et al



Oral presentation Summary Poster P5.06: Targeted delivery of a microRNA mimic as a novel approach to therapy for malignant pleural mesothelioma

Speakers

Glen Reid, et al


WIN CHAIRMAN’S LECTURE:

Personalized cancer therapy: Successes and challenges

Speakers

John Mendelsohn


Plenary Session 3:
Tuesday, June 24, 2014

Combinations of targeted therapies (part 1)

Speakers


Keynote Lecture:

Complexity of intra- and inter-pathway loops in colon cancer and melanoma: Implications for targeted therapies

Speakers

Rene Bernards



Genomic complexity of metastatic disease and the conundrum of combinations

Speakers

Razelle Kurzrock



Biology driven combination therapies: How to turn up the HEAT on cancer – A PhRMA perspective

Speakers



Combinations of targeted therapies in oncology – An industry view

Speakers

Susan Galbraith



General Discussion, session 4

Speakers


Plenary Session 4:
Tuesday, June 24, 2014

Combinations of targeted therapies (part 2)

Speakers



The challenges of combinations of targeted agents in oncology

Speakers

Tal Zaks



Impact of the BATTLE trial

Speakers

Waun Ki Hong



Combining radiotherapy with immunotherapy in metastatic cancer

Speakers

Silvia Formenti


Keynote Lecture:

Growing tissue stem cells into organoids and tumeroids: Predictive assay development

Speakers

Hans Clevers


Plenary Session 5:
Tuesday, June 24, 2014

New findings on fundamental mechanisms in pediatric cancers

Speakers


Keynote Lecture:

Novel drug targets and potential combinations in childhood brain tumors

Speakers

Stefan Pfister



Pediatric high grade brain tumors: Epigenetic addiction of the developing brain?

Speakers

Nada Jabado


WIN 2014 SPECIAL KEYNOTE LECTURE:

Cancer Stem Cells and Malignant Progression

Speakers

Robert Weinberg


Plenary Session 6:
Tuesday, June 24, 2014

Blood and fluids – non-invasive investigations in oncology

Speakers


Keynote Lecture:

Proactive P4 medicine-making blood a window into health and disease: A tipping point that is transforming healthcare

Speakers

Leroy Hood



Circulating tumor cells (CTCs) or circulating DNA (cfDNA): What are the perspectives?

Speakers

Caroline Dive



Personalized cancer medicine using the human protein atlas and affibodies

Speakers

Mathias Uhlen



Wrap-up and conclusions

Speakers


WIN 2013 Symposium

WIN 2013 Symposium
July 10 - 12, 2013

The WIN 2013 Symposium, held on the theme of “Personalized Cancer Medicine: From Innovation to Implementation” drew over 400 delegates from around the world. Thirty experts from academia, pharma, diagnostics, bio-informatics companies, and regulatory agencies presented and discussed their views on how new genomic and proteomic technologies and new targeted therapies affect the way individual cancer patients are treated, as well as the hurdles for implementation of personalized cancer therapy in innovative clinical trials and daily practice.